Press Releases

 
Press Releases
  Date Title and Summary View
  Feb 28, 2011
  Sep 29, 2010
Feb 17, 2010
SAN FRANCISCO, February 17, 2010 – The first-ever-reported Phase II data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, demonstrate that the CCR5 receptor antagonist provides potent antiviral activity and is generally safe and well-tolerated in its proof of concept trial....
Feb 17, 2010
SAN FRANCISCO, February 17, 2010 – Pharmacokinetic/pharmacodynamic (PK/PD) data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, show a strong relationship between drug exposure and viral suppression with this next-generation CCR5 receptor antagonist. These data were ...
Nov 12, 2009
Princeton, NJ and San Diego, CA, November 12, 2009 – Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-con...
Jul 22, 2009
Princeton, NJ and San Diego, CA, July 22, 2009 – Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic stud...
Jun 4, 2009
PRINCETON, N.J. and SAN DIEGO, June 4, 2009 /PRNewswire via COMTEX/ – Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the addition of Roscoe Moore Jr., D.V.M., Ph.D., D.Sc. to their ...
Apr 8, 2009
Princeton, NJ and San Diego, CA, April Princeton, NJ and San Diego, CA, April 8, 2009 – Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced that it has initiated a proof-of-concept study...
Aug 18, 2008
Princeton, NJ and San Diego, CA, August 18, 2008 – Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the issuance of Patent No. 7,371,772 B2 by the U.S. Patent and Trademark Office, co...
  Jun 30, 2008
Page: FirstPrevious ...
8
= add release to Briefcase